VRTX · Vertex Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $126.7B |
| P/E | 28.75 |
| Float | 253.2M |
| Beta | 0.29 |
| Volatility | 7.2% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79.6 |
| Price | 504.77 |
| Change | +1.01% |
| Prev Close | 499.74 |
| Open | 511.06 |
| Day Low | 497.49 |
| Day High | 512.21 |
| Avg Vol | 1 |
| Avg $ Vol | $668.3M |
| 52W High | 560.25 |
| 52W Low | 403.16 |
| 52W Pos | 64.7% |
| From High | −9.90% |
| From Low | +25.20% |
| Max DD 1Y | −15.21% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −1.06% |
| SMA 50 | −3.40% |
| SMA 200 | +6.07% |
| RSI (14) | 43.8 |
| Vol 30D | 24.5% |
| Vol 90D | 28.5% |
| 1Y Range | 403–560 |
| Daily bars | 536 |
| Perf Week | −2.03% |
| Perf Month | −3.21% |
| Perf Quarter | +4.00% |
| Perf Half Y | +13.27% |
| Perf Year | +22.52% |
| Perf YTD | +11.64% |
| Prev Day | +1.01% |
| Clavix | B+ |
| Debt / Eq | 0.01 |
| Curr Ratio | 2.90 |
| Int Cover | 16.9× |
| FCF Margin | 26.6% |
| Rev Growth | +8.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 3 / 35 |
What VRTX does
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics.
Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Clavix risk grade
regraded every trading dayVRTX grades B+, 79.6 of 100. Steadiest on Macro Resilience (67), most exposed on Sector Resilience (54, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 3 of 35 in Biotechnology by Clavix score.
How rough the ride is
| VRTX | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.29 | 0.51 |
| Volatilityannualized | 7.2% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −15.2% | — |
| Typical daily movemedian absolute daily change | 1.01% | — |
| Days beyond ±3%of the last 252 sessions | 22 (9%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VRTX | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.29 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VRTX | |
|---|---|
| 1 week | −2.0% |
| 1 month | −3.2% |
| Year to date | +11.6% |
| 1 year | +22.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VRTX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 12 Sep |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 2 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| VRTX | |
|---|---|
| Revenue growthyear over year | +8.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openVertex Pharmaceuticals presented new interim data on its cystic fibrosis drug ALYFTREK at a medical conference, showing some young children regained pancreatic function and were able to stop taking enzyme replacement therapy (digestive enzyme pills used when the pancreas doesn't produce enough on its own). The company's share price has been mixed, down 1.77% over one day and 2.63% over 30 days, but up 2.90% over 90 days.
Wall Street Zen upgraded its rating on Vertex Pharmaceuticals (VRTX) from 'hold' to 'buy' in a research note issued Saturday. No price target, rationale or additional detail was provided in the report.
This article is about Vertex, Inc. (NASDAQ:VERX), a tax compliance software company, not Vertex Pharmaceuticals (VRTX). It announces that Vertex, Inc.'s O Series Tax Engine for Oracle has been validated for Oracle Cloud Infrastructure and is available on the Oracle Marketplace.
Wall Street Zen downgraded Vertex, which trades on NASDAQ as VERX, from a 'buy' rating to a 'hold' rating, according to a report published Saturday. The article contains no further details.
Vertex Pharmaceuticals announced new interim data from an ongoing study of its cystic fibrosis drug ALYFTREK in children aged 2 to 5, showing that some of those children regained pancreatic function and were able to stop taking enzyme replacement pills. The company is presenting the findings at the North American Cystic Fibrosis Conference.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
| GILD | Gilead Sciences, Inc | A- | $193.7B | 22.76 | 0.40 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
| AMGN | Amgen Inc | A- | $233.8B | 26.74 | 0.44 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| ABBV | AbbVie Inc | B+ | $504.4B | 79.93 | 0.19 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.